Bausch Health Companies Inc. (TSE:BHC - Get Free Report) Director John Paulson bought 1,782,030 shares of the stock in a transaction on Friday, June 13th. The shares were acquired at an average cost of C$8.14 per share, for a total transaction of C$14,501,803.73.
John Paulson also recently made the following trade(s):
- On Thursday, June 12th, John Paulson purchased 502,688 shares of Bausch Health Companies stock. The shares were bought at an average price of C$7.44 per share, with a total value of C$3,739,596.57.
- On Wednesday, June 11th, John Paulson acquired 514,549 shares of Bausch Health Companies stock. The shares were bought at an average cost of C$7.13 per share, for a total transaction of C$3,666,881.99.
- On Tuesday, June 10th, John Paulson bought 754,134 shares of Bausch Health Companies stock. The stock was bought at an average price of C$6.87 per share, with a total value of C$5,179,392.31.
Bausch Health Companies Stock Performance
Bausch Health Companies stock traded down C$0.21 during trading hours on Tuesday, reaching C$7.80. 373,153 shares of the company were exchanged, compared to its average volume of 357,009. Bausch Health Companies Inc. has a 12 month low of C$5.45 and a 12 month high of C$13.74. The firm has a market cap of C$2.03 billion, a price-to-earnings ratio of -11.41, a PEG ratio of 0.21 and a beta of 0.77. The company has a current ratio of 1.19, a quick ratio of 0.58 and a debt-to-equity ratio of -1,831.94. The stock has a 50-day moving average of C$6.74 and a 200 day moving average of C$9.08.
About Bausch Health Companies
(
Get Free Report)
Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Bausch Health Companies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch Health Companies wasn't on the list.
While Bausch Health Companies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
